HOOKIPA doses first patient in HB-201 Phase 1/2 trial for HPV16+ cancers
Category: #headlines  By Anchal Solanki  Date: 2019-12-31
  • share
  • Twitter
  • Facebook
  • LinkedIn
HOOKIPA doses first patient in HB-201 Phase 1/2 trial for HPV16+ cancers

 

  • HB-201 is an immunotherapy to treat Human Papillomavirus 16-positive (HPV16+) cancers
  • HPV has been estimated to cause nearly 5% of cancers worldwide, majorly due to HPV serotype 16

HOOKIPA Pharma Inc.,  a developer of immunotherapeutics that target cancers and other infectious diseases based primarily on its proprietary arenavirus platform, recently announced that dosing for the first patient was completed in HB-201’s Phase 1/2 clinical trial (NCT04180215).

HB-201 is an immunotherapy to treat Human Papillomavirus 16-positive (HPV16+) cancers. It will be the first clinical trial in immuno-oncology for HOOKIPA.

Apparently, HB-201 is essentially a TheraT platform-based vector that comes from the arenavirus family while expressing a highly antigenic and a non-oncogenic E6/E7 fusion protein from the HPV16. HB-201, under the preclinical studies, had been observed to be extremely immunogenic which would result in a sturdy CD8+T cell response in comparison to the levels that were induced by other approaches, which include adoptive cell therapies. 

HOOKIPA also observed a strong anti-tumor activity in the mouse models besides exhibiting a strong immunogenicity. The company firmly believes that HB-201 has the potential to help provide a therapeutic advantage to patients in the HPV16+ cancer setting.

HOOKIPA’s Chief Executive Officer, Joern Aldag stated that the company is looking forward to starting the first-in-human testing with the help of HB-201, its first clinical trial in immune-oncology. The translation of promising preclinical data for all cancer patients will be an important milestone for the company.  

Aldag further added that the approach of the company is capable of supercharging the natural defense mechanisms by having induced sturdy T cell responses for the benefit of the patients who are affected by infectious diseases and cancer.

THE HB-201 Phase 1/2 trial is basically an open-label dose-escalation as well as a dose-expansion trial to be done in 100 patients suffering from treatment-refractory HPV16+ cancers. It has been designed for the evaluation of tolerability and safety as well as preliminary efficacy of the HB-201 as a monotherapy and for combination therapy with an immune checkpoint inhibitor.

 

Source credit- https://ir.hookipapharma.com/news-releases/news-release-details/hookipa-announces-first-patient-dosed-phase-12-clinical-trial-hb

  • share
  • Twitter
  • Facebook
  • LinkedIn

About Author

Anchal Solanki

Anchal Solanki    

A civil engineer by qualification, Anchal Solanki forayed into the domain of content writing in the midst of her graduation, embarking on the career path of a successful freelancer. Equipped with a short-term experience in market research, Anchal currently writes news...

Read More >>

More News By Anchal Solanki

TalkTalk sells broadband business to CityFibre for £200 million
TalkTalk sells broadband business to CityFibre for £200 million
By Anchal Solanki

TalkTalk is set to trim its debt with the sale of the FibreNation division for £200 million. Acquisition of FibreNation by CityFibre incorporates a wholesale commitment which would need TalkTalk to provide its customers broadband services which...

Clairvest leads its sixth minor growth equity financing in DTG Recycle
Clairvest leads its sixth minor growth equity financing in DTG Recycle
By Anchal Solanki

The deal is done to support the company’s expansion in the Pacific Northwest. This will be Clairvest’s sixth investment in the waste management industry. Clairvest Group Inc., an equity management company, recently announced that it...

Qatar to develop a 800MW solar power plant with Total & Marubeni
Qatar to develop a 800MW solar power plant with Total & Marubeni
By Anchal Solanki

Like most of its oil-rich neighbors, Qatar seems to be pushing towards solar power to meet its local energy needs. The nation, being one of the leading exporter of LNG (liquefied natural gas) across the globe, has reportedly inked an agreement with J...